NEPENTHE
Neuropathy, Painful
Nova Scotia Health AuthoritySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Neuropathy, Painful cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Dfn-15 Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Naltrexone Emory University | Phase 4 | BB |
FENTANYL Cephalon | Phase 3 | B |
Lacosamide Danish Pain Research Center | Phase 2 | B |
View all 19 →
Same molecule, other indications
NEPENTHE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →